Currently, due to the high mutation rate of KRAS, it is reported that biopsy is performed to diagnose pancreatic cancer with pathological outcome and with mutated KRAS.3 p53, CDKN2A, and SMAD4 are tumour suppressor genes, and in pancreatic cancer, mutations have been observed in ~50–70% of p53 and in 30–50% of CDKN2A and SMAD4.2 In pancreatic cancer, p53 mutations are controversial, although they have been reported to correlate with worse prognosis.4 This evidence concerns the gene KRAS and pancreatic neoplasm.